#BEGIN_DRUGCARD DB01044

# AHFS_Codes:
52:04.04

# ATC_Codes:
J01MA16
S01AE06

# Absorption:
Well absorbed from the gastrointestinal tract after oral administration with absolute bioavailability of gatifloxacin is 96%

# Biotransformation:
Gatifloxacin undergoes limited biotransformation in humans with less than 1% of the dose excreted in the urine as ethylenediamine and methylethylenediamine metabolites

# Brand_Mixtures:
Not Available

# Brand_Names:
Tequin
Zymar

# CAS_Registry_Number:
112811-59-3

# ChEBI_ID:
5280

# Chemical_Formula:
C19H22FN3O4

# Chemical_IUPAC_Name:
1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2243181

# Description:
Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. Bristol-Myers Squibb introduced Gatifloxacin in 1999 under the proprietary name Tequin® for the treatment of respiratory tract infections, having licensed the medication from Kyorin Pharmaceutical Company of Japan. Allergan produces an eye-drop formulation called Zymar®. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. [Wikipedia]

# Dosage_Forms:
Solution	Ophthalmic

# Drug_Category:
Anti-Infective Agents
Antibiotics
Quinolones

# Drug_Interactions:
Aluminium	Formation of non-absorbable complexes
Amiodarone	Increased risk of cardiotoxicity and arrhythmias
Bepridil	Increased risk of cardiotoxicity and arrhythmias
Bretylium	Increased risk of cardiotoxicity and arrhythmias
Chlorpromazine	Increased risk of cardiotoxicity and arrhythmias
Digoxin	Gatifloxacin increases the effect of digoxin
Dihydroquinidine barbiturate	Increased risk of cardiotoxicity and arrhythmias
Disopyramide	Increased risk of cardiotoxicity and arrhythmias
Fluphenazine	Increased risk of cardiotoxicity and arrhythmias
Iron	Formation of non-absorbable complexes
Iron Dextran	Formation of non-absorbable complexes
Magnesium	Formation of non-absorbable complexes
Magnesium oxide	Formation of non-absorbable complexes
Magnesium salicylate	Formation of non-absorbable complexes
Mesoridazine	Increased risk of cardiotoxicity and arrhythmias
Methotrimeprazine	Increased risk of cardiotoxicity and arrhythmias
Perphenazine	Increased risk of cardiotoxicity and arrhythmias
Prochlorperazine	Increased risk of cardiotoxicity and arrhythmias
Promazine	Increased risk of cardiotoxicity and arrhythmias
Promethazine	Increased risk of cardiotoxicity and arrhythmias
Propiomazine	Increased risk of cardiotoxicity and arrhythmias
Quinidine	Increased risk of cardiotoxicity and arrhythmias
Quinidine barbiturate	Increased risk of cardiotoxicity and arrhythmias
Quinupristin	This combination presents an increased risk of toxicity
Sotalol	Increased risk of cardiotoxicity and arrhythmias
Sucralfate	Formation of non-absorbable complexes
Tacrolimus	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
Thiethylperazine	Increased risk of cardiotoxicity and arrhythmias
Thioridazine	Increased risk of cardiotoxicity and arrhythmias
Thiothixene	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
Toremifene	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
Trifluoperazine	Increased risk of cardiotoxicity and arrhythmias
Triflupromazine	Increased risk of cardiotoxicity and arrhythmias
Trimipramine	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
Voriconazole	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Vorinostat	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Zinc	Formation of non-absorbable complexes
Ziprasidone	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.

# Drug_Reference:
16510739	Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, Dresser L, Low DE, Mamdani MM: Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med. 2006 Mar 30;354(13):1352-61. Epub 2006 Mar 1.
16510740	Gurwitz JH: Serious adverse drug effects--seeing the trees through the forest. N Engl J Med. 2006 Mar 30;354(13):1413-5. Epub 2006 Mar 1.

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
2.6

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
60 mg/mL (at pH 4)

# Food_Interactions:
Absorption does not seem to be affected by milk or calcium carbonate, however, gatifloxacin bioavailability appears significantly reduced when combined with Ensure&trade; (C<sub>max</sub> is reduced by about 50% while total drug exposure (AUC) is reduced by about 25%).
Drink liberally.
Take without regard to meals.

# GenBank_ID:
Not Available

# Generic_Name:
Gatifloxacin

# HET_ID:
Not Available

# Half_Life:
7-14 hours

# InChI_Identifier:
InChI=1S/C19H22FN3O4/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26)

# InChI_Key:
InChIKey=XUBOMFCQGDBHNK-UHFFFAOYSA-N

# Indication:
For the treatment of bronchitis, sinusitis, community-acquired pneumonia, and skin infections (abscesses, wounds) caused by S. pneumoniae, H. influenzae, S. aureus, M. pneumoniae, C. pneumoniae, L. pneumophila, S. pyogenes

# KEGG_Compound_ID:
C07661

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1044

# Mechanism_Of_Action:
The bactericidal action of Gatifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.

# Melting_Point:
182-185 °C

# Molecular_Weight_Avg:
375.3941

# Molecular_Weight_Mono:
375.159434412

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/zym1676.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA449738

# Pharmacology:
Gatifloxacin is a synthetic broad-spectrum 8-methoxyfluoroquinolone antibacterial agent for oral or intravenous administration. is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Gatifloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. It should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

# Predicted_LogP_Hydrophobicity:
-0.23

# Predicted_LogS:
-2.8

# Predicted_Water_Solubility:
6.31e-01 g/l

# Primary_Accession_No:
DB01044

# Protein_Binding:
20%

# PubChem_Compound_ID:
5379

# PubChem_Substance_ID:
46506159

# RxList_Link:
http://www.rxlist.com/cgi/generic3/gatifloxacin.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00996

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-06-10 00:23:38 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Gatifloxacin

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11131958	Harding I, Simpson I: Fluoroquinolones: is there a different mechanism of action and resistance against Streptococcus pneumoniae? J Chemother. 2000 Oct;12 Suppl 4:7-15.
11178337	Kim OK, Ohemeng K, Barrett JF: Advances in DNA gyrase inhibitors. Expert Opin Investig Drugs. 2001 Feb;10(2):199-212.
12835539	Hosaka M: [Antibacterial property and clinical effect of gatifloxacin, a novel quinolone antibacterial agent] Nippon Yakurigaku Zasshi. 2003 Jun;121(6):447-56.
15673722	Rafii F, Park M, Novak JS: Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones. Antimicrob Agents Chemother. 2005 Feb;49(2):488-92.
17253913	Kays MB, Zhanel GG, Reimann MA, Jacobi J, Denys GA, Smith DW, Wack MF: Selection of a gyrA mutation and treatment failure with gatifloxacin in a patient with Streptococcus pneumoniae with a preexisting parC mutation. Pharmacotherapy. 2007 Feb;27(2):221-6.
17970226	Mdluli K, Ma Z: Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect Disord Drug Targets. 2007 Jun;7(2):159-68.

# Drug_Target_1_Essentiality:
Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
AE005672

# Drug_Target_1_GenBank_ID_Protein:
14971465

# Drug_Target_1_GeneCard_ID:
gyrA

# Drug_Target_1_Gene_Name:
gyrA

# Drug_Target_1_Gene_Sequence:
>1362 bp
TTGAAAGAAAAACAATTTTGGAATCGTATATTAGAATTTGCACAAGAAAGACTGACTCGA
TCCATGTATGATTTCTATGCTATTCAAGCTGAACTCATCAAGGTAGAGGAAAATGTTGCC
ACTATATTTCTACCTCGCTCTGAAATGGAAATGGTCTGGGAAAAACAACTAAAAGATATT
ATTGTAGTAGCTGGTTTTGAAATTTATGACGCTGAAATAACTCCCCACTATATTTTCACC
AAACCTCAAGATACGACTAGCTCACAAGTTGAAGAAGCTACAAATTTAACTCTTTATAAC
TATAGTCCAAAGTTAGTATCTATTCCTTATTCAGATACGGGATTAAAAGAAAAGTATACC
TTTGATAACTTTATTCAAGGGGATGGAAATGTTTGGGCTGTATCAGCCGCTTTAGCTGTC
TCTGAAGATTTGGCTCTGACCTATAACCCTCTTTTTATCTATGGAGGACCAGGCCTTGGT
AAGACTCACTTATTAAACGCTATTGGAAATGAAATTCTAAAAAATATTCCTAATGCGCGT
GTTAAATATATCCCTGCCGAAAGCTTTATTAATGACTTTCTTGATCACCTAAGACTTGGG
GAAATGGAAAAGTTTAAAAAGACCTATCGTAGTCTTGATCTTTTGTTAATCGATGATATC
CAGTCACTCAGCGGAAAAAAAGTCGCAACTCAGGAAGAATTTTTCAATACCTTTAACGCC
CTTCATGACAAGCAAAAACAGATTGTCCTAACGAGTGATCGTAGTCCAAAACATCTAGAA
GGGCTCGAGGAGAGGCTTGTCACGCGTTTTAGTTGGGGATTGACACAAACTATCACCCCC
CCTGACTTTGAAACACGTATTGCCATTTTACAAAGTAAGACGGAACATTTAGGCTACAAT
TTCCAAAGTGATACTCTAGAATACCTAGCTGGGCAATTTGATTCAAATGTTCGAGATCTT
GAGGGAGCCATCAACGACATCACTTTAATTGCCAGAGTAAAAAAAATCAAGGATATCACT
ATTGATATTGCTGCAGAAGCCATTAGAGCCCGCAAACAAGATGTTAGCCAAATGCTCGTC
ATCCCAATTGATAAAATCCAAACTGAAGTTGGTAACTTTTATGGTGTTAGTATCAAAGAA
ATGAAGGGAAGTAGACGCCTTCAAAATATTGTTTTGGCCCGTCAAGTAGCCATGTATTTA
TCTAGAGAACTAACAGATAATAGTCTTCCAAAAATTGGGAAGGAATTTGGGGGAAAAGAT
CATACCACAGTCATTCATGCCCATGCCAAAATAAAATCTTTGATTGATCAAGACGATAAT
TTACGTTTAGAAATTGAATCAATCAAAAAGAAAATCAAATAA

# Drug_Target_1_General_Function:
Replication, recombination and repair

# Drug_Target_1_General_References:
11463916	Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, Peterson S, Heidelberg J, DeBoy RT, Haft DH, Dodson RJ, Durkin AS, Gwinn M, Kolonay JF, Nelson WC, Peterson JD, Umayam LA, White O, Salzberg SL, Lewis MR, Radune D, Holtzapple E, Khouri H, Wolf AM, Utterback TR, Hansen CL, McDonald LA, Feldblyum TV, Angiuoli S, Dickinson T, Hickey EK, Holt IE, Loftus BJ, Yang F, Smith HO, Venter JC, Dougherty BA, Morrison DA, Hollingshead SK, Fraser CM: Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science. 2001 Jul 20;293(5529):498-506.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
6224

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
92052.6

# Drug_Target_1_Name:
DNA gyrase subunit A

# Drug_Target_1_Number_of_Residues:
822

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00521	DNA_topoisoIV
PF03989	DNA_gyraseA_C

# Drug_Target_1_Protein_Sequence:
>DNA gyrase subunit A
MQDKNLVNVNLTKEMKASFIDYAMSVIVARALPDVRDGLKPVHRRILYGMNELGVTPDKP
HKKSARITGDVMGKYHPHGDSSIYEAMVRMAQWWSYRYMLVDGHGNFGSMDGDSAAAQRY
TEARMSKIALEMLRDINKNTVDFVDNYDANEREPLVLPARFPNLLVNGATGIAVGMATNI
PPHNLGETIDAVKLVMDNPEVTTKDLMEVLPGPDFPTGALVMGKSGIHKAYETGKGSIVL
RSRTEIETTKTGRERIVVTEFPYMVNKTKVHEHIVRLVQEKRIEGITAVRDESNREGVRF
VIEVKRDASANVILNNLFKMTQMQTNFGFNMLAIQNGIPKILSLRQILDAYIEHQKEVVV
RRTRFDKEKAEARAHILEGLLIALDHIDEVIRIIRASETDAEAQAELMSKFKLSERQSQA
ILDMRLRRLTGLERDKIQSEYDDLLALIADLADILAKPERVSQIIKDELDEVKRKFSDKR
RTELMIGQVLSLEDEDLIEESDVLITLSNRGYIKRLDQDEFTAQKRGGRGVQGTGVKDDD
FVRELVSTSTHDHLLFFTNKGRVYRLKGYEIPEYGRTAKGLPVVNLLKLDEDESIQTVIN
VESDRSDDAYLFFTTRHGIVKRTSVKEFANIRQNGLKALNLKDEDELINVLLAEGDMDII
IGTKFGYAVRFNQSAVRGMSRIATGVKGVNLREGDTVVGASLITDQDEVLIITEKGYGKR
TVATEYPTKGRGGKGMQTAKITEKNGLLAGLMTVQGDEDLMIITDTGVMIRTNLANISQT
GRATMGVKVMRLDQDAQIVTFTTVAVAEKEEVGTENETEGEA

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
DNA gyrase negatively supercoils closed circular double- stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings

# Drug_Target_1_SwissProt_ID:
P72524

# Drug_Target_1_SwissProt_Name:
GYRA_STRPN

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
6.07

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasmic

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
11131958	Harding I, Simpson I: Fluoroquinolones: is there a different mechanism of action and resistance against Streptococcus pneumoniae? J Chemother. 2000 Oct;12 Suppl 4:7-15.
11178337	Kim OK, Ohemeng K, Barrett JF: Advances in DNA gyrase inhibitors. Expert Opin Investig Drugs. 2001 Feb;10(2):199-212.
12835539	Hosaka M: [Antibacterial property and clinical effect of gatifloxacin, a novel quinolone antibacterial agent] Nippon Yakurigaku Zasshi. 2003 Jun;121(6):447-56.
15673722	Rafii F, Park M, Novak JS: Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones. Antimicrob Agents Chemother. 2005 Feb;49(2):488-92.
17253913	Kays MB, Zhanel GG, Reimann MA, Jacobi J, Denys GA, Smith DW, Wack MF: Selection of a gyrA mutation and treatment failure with gatifloxacin in a patient with Streptococcus pneumoniae with a preexisting parC mutation. Pharmacotherapy. 2007 Feb;27(2):221-6.
17970226	Mdluli K, Ma Z: Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect Disord Drug Targets. 2007 Jun;7(2):159-68.

# Drug_Target_2_Essentiality:
Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
X83917

# Drug_Target_2_GenBank_ID_Protein:
1052803

# Drug_Target_2_GeneCard_ID:
gyrB

# Drug_Target_2_Gene_Name:
gyrB

# Drug_Target_2_Gene_Sequence:
>1947 bp
ATGACAGAAGAAATCAAAAATCTGCAGGCACAGGATTATGATGCCAGTCAAATTCAAGTT
TTAGAGGGCTTAGAGGCTGTTCGTATGCGTCCAGGGATGTACATTGGATCAACCTCAAAA
GAAGGTCTTCACCATCTAGTCTGGGAAATTGTTGATAACTCAATTGACGAGGCCTTGGCA
GGATTTGCCAGCCATATTCAAGTTTTTATTGAGCCAGATGATTCGATTACTGTTGTGGAT
GATGGGCGTGGTATCCCAGTCGGTATTCAGGAAAAAACAGGTCGTCCTGCTGTTGAGACC
GTCTTTACAGTCCTTCACTCTGGAGGAAAGTTCGGCGGTGGTGGATACAAGGTTTCAGGT
GGTCTTCACGGGGTGGGGTTGTCAGTTGTTAATGCCCTTTCCACTCAATTAGACGTTCAT
GTCCATAAAAACGGTAAGATTCATTACCAAGAATACCGTCGTGGTCATGTTGTCGCAGAT
CTTGAAATAGTTGGAGATACGGATAAAACAGGAACAACTGTTCACTTCACACCGGACCCA
AAAATCTTCACTGAAACAACAATCTTTGATTTTGATAAATTAAATAAACGGATTCAAGAG
TTGGCCTTTCTAAATCGCGGTCTTCAAATTTCTATCACTGATAAGCGCCAAGGTTTGGAA
CAAACCAAGCATTATCATTATGAAGGTGGGATTGCTAGTTACGTTGAATATATCAACGAG
AACAAGGATGTAATCTTTGATACACCAATCTATACAGACGGTGAGATGGATGATATCACA
GTTGAGGTAGCCATGCAGTACACAACGGGTTACCATGAAAATGTCATGAGTTTCGCCAAT
AATATTCATACACATGAAGGTGGAACGCATGAACAAGGTTTCCGTACAGCCTTGACACGT
GTTATCAACAGTTATGCTCGTAAGAATAAGTTACTGAAAGACAATGAAGACAATCTAACA
GGGGAAGATGTTCGCGAAGGCTTAACTGCAGTTATCTCAGTTAAACACCCAAATCCACAG
TTTGAAGGACAAACGAAGACCAAATTGGGAAATAGCGAAGTGGTCAAGATTACCAATCGC
CTCTTCAGTGAAGCCTTCTCCGATTTCCTCATGGAAAATCCACAGATTGCCAAACGTATC
GTAGAAAAAGGAATTTTGGCTGCCAAGGCTCGTGTGGCTGCCAAGCGTGCGCGTGAAGTC
ACACGTAAAAAATCTGGTTTGGAAATTTCCAACCTTCCAGGGAAACTAGCAGACTGTTCT
TCTAATAACCCTGCTGAAACAGAACTCTTCATCGTCGAAGGAGACTCAGCTGGTGGATCA
GCCAAATCTGGTCGTAACCGTGAGTTTCAGGCTATCCTTCCAATTCGCGGTAAGATTTTG
AACGTTGAAAAAGCAAGTATGGATAAGATTCTAGCTAACGAAGAAATTCGTAGTCTTTTC
ACAGCCATGGGAACAGGATTTGGCGCAGAATTTGATGTTTCGAAAGCCCGTTACCAAAAA
CTCGTTTTGATGACCGATGCCGATGTCGATGGAGCCCACATTCGTACCCTTCTTTTAACC
TTGATTTATCGTTATATGAAACCAATCCTAGAAGCTGGCTATGTTTATATTGCCCAACCA
CCAATCTATGGTGTCAAGGTTGGAAGCGAGATTAAAGAATATATCCAGCCGGGTGCAGAT
CAAGAAATCAAACTCCAAGAAGCTTTAGCCCGTTATAGTGAAGGTCGTACCAAACCGACT
ATTCAGCGTTATAAGGGGCTAGGTGAAATGGACGATCATCAGCTGTGGGAAACAACCATG
GATCCCGAACATCGCTTGATGGCTAGAGTTTCTGTAGATGATGCTGCAGAAGCAGATAAA
ATCTTTGATATGTTGATGGGGGATCGAGTAGAGCCTCGTCGTGAGTTTATCGAAGAAAAT
GCTGTCTATAGTACACTTGATGTCTAA

# Drug_Target_2_General_Function:
Replication, recombination and repair

# Drug_Target_2_General_References:
11463916	Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, Peterson S, Heidelberg J, DeBoy RT, Haft DH, Dodson RJ, Durkin AS, Gwinn M, Kolonay JF, Nelson WC, Peterson JD, Umayam LA, White O, Salzberg SL, Lewis MR, Radune D, Holtzapple E, Khouri H, Wolf AM, Utterback TR, Hansen CL, McDonald LA, Feldblyum TV, Angiuoli S, Dickinson T, Hickey EK, Holt IE, Loftus BJ, Yang F, Smith HO, Venter JC, Dougherty BA, Morrison DA, Hollingshead SK, Fraser CM: Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science. 2001 Jul 20;293(5529):498-506.
7608096	Munoz R, Bustamante M, de la Campa AG: Ser-127-to-Leu substitution in the DNA gyrase B subunit of Streptococcus pneumoniae is implicated in novobiocin resistance. J Bacteriol. 1995 Jul;177(14):4166-70.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
6225

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
72237.0

# Drug_Target_2_Name:
DNA gyrase subunit B

# Drug_Target_2_Number_of_Residues:
648

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00204	DNA_gyraseB
PF00986	DNA_gyraseB_C
PF01751	Toprim
PF02518	HATPase_c

# Drug_Target_2_Protein_Sequence:
>DNA gyrase subunit B
MTEEIKNLQAQDYDASQIQVLEGLEAVRMRPGMYIGSTSKEGLHHLVWEIVDNSIDEALA
GFASHIQVFIEPDDSITVVDDGRGIPVDIQEKTGRPAVETVFTVLHAGGKFGGGGYKVSG
GLHGVGSSVVNALSTQLDVHVHKNGKIHYQEYRRGHVVADLEIVGDTDKTGTTVHFTPDP
KIFTETTIFDFDKLNKRIQELAFLNRGLQISITDKRQGLEQTKHYHYEGGIASYVEYINE
NKDVIFDTPIYTDGEMDDITVEVAMQYTTGYHENVMSFANNIHTHEGGTHEQGFRTALTR
VINDYARKNKLLKDNEDNLTGEDVREGLTAVISVKHPNPQFEGQTKTKLGNSEVVKITNR
LFSEAFSDFLMENPQIAKRIVEKGILAAKARVAAKRAREVTRKKSGLEISNLPGKLADCS
SNNPAETELFIVEGDSAGGSAKSGRNREFQAILPIRGKILNVEKASMDKILANEEIRSLF
TAMGTGFGAEFDVSKARYQKLVLMTDADVDGAHIRTLLLTLIYRYMKPILEAGYVYIAQP
PIYGVKVGSEIKEYIQPGADQEIKLQEALARYSEGRTKPTIQRYKGLGEMDDHQLWETTM
DPEHRLMARVSVDDAAEADKIFDMLMGDRVEPRREFIEENAVYSTLDV

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
DNA gyrase negatively supercoils closed circular double- stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings

# Drug_Target_2_SwissProt_ID:
P0A4L9

# Drug_Target_2_SwissProt_Name:
GYRB_STRPN

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
5.28

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cell membrane

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
11131958	Harding I, Simpson I: Fluoroquinolones: is there a different mechanism of action and resistance against Streptococcus pneumoniae? J Chemother. 2000 Oct;12 Suppl 4:7-15.
12835539	Hosaka M: [Antibacterial property and clinical effect of gatifloxacin, a novel quinolone antibacterial agent] Nippon Yakurigaku Zasshi. 2003 Jun;121(6):447-56.
15673722	Rafii F, Park M, Novak JS: Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones. Antimicrob Agents Chemother. 2005 Feb;49(2):488-92.
17253913	Kays MB, Zhanel GG, Reimann MA, Jacobi J, Denys GA, Smith DW, Wack MF: Selection of a gyrA mutation and treatment failure with gatifloxacin in a patient with Streptococcus pneumoniae with a preexisting parC mutation. Pharmacotherapy. 2007 Feb;27(2):221-6.
17970226	Mdluli K, Ma Z: Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect Disord Drug Targets. 2007 Jun;7(2):159-68.

# Drug_Target_3_Essentiality:
Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
Z67739

# Drug_Target_3_GenBank_ID_Protein:
1490399

# Drug_Target_3_GeneCard_ID:
parC

# Drug_Target_3_Gene_Name:
parC

# Drug_Target_3_Gene_Sequence:
>1944 bp
GTGTCAAAAAAGGAAATCAATATTAACAATTATAATGATGATGCTATTCAGGTGCTAGAA
GGGTTGGATGCGGTCCGAAAACGTCCGGGGATGTATATTGGATCGACCGATGGCGCTGGT
CTTCATCACCTAGTTTGGGAAATCGTTGATAATGCAGTCGATGAAGCCTTGTCTGGGTTT
GGTGATCGTATTGATGTAACTATCAATAAAGACGGTAGTCTAACGGTTCAAGACCATGGA
CGTGGGATGCCGACAGGTATGCACGCTATGGGAATTCCAACTGTTGAGGTTATCTTTACC
ATTCTTCATGCCGGAGGGAAATTCGGTCAAGGTGGCTATAAGACATCAGGTGGACTTCAC
GGAGTGGGTTCTTCCGTTGTTAACGCCCTTTCTAGCTGGTTAGAAGTTGAAATTACCCGT
GATGGCGCAGTTTACAAGCAACGTTTCGAAAATGGTGGAAAACCTGTCACGACTTTGAAG
AAAATCGGTACAGCACCCAAGTCTAAAACAGGCACCAAAGTTACTTTTATGCCTGACGCG
ACTATATTTTCTACGACAGATTTCAAGTACAATACCATTTCAGAGCGCCTTAATGAATCA
GCCTTTCTCTTGAAAAATGTGACCTTGTCTTTAACGGACAAGCGAACAGATGAAGCGATT
GAGTTCCACTATGAGAATGGAGTACAAGATTTTGTTTCTTATCTCAACGAAGATAAGGAA
ATCTTGACGCCAGTTCTTTACTTTGAAGGGGAAGACAATGGTTTTCAAGTGGAAGTAGCC
CTCCAGTACAATGACGGATTCTCAGATAACATTCTATCCTTTGTCAATAACGTTCGCACC
AAGGACGGTGGAACGCACGAGACAGGACTCAAGTCTGCCATTACCAAGGTCATGAATGAC
TATGCACGTAAAACAGGTCTTCTCAAGGAAAAAGATAAAAACCTTGAAGGTTCAGACTAT
CGTGAGGGACTAGCGGCCGTTCTTTCTATCTTAGTTCCTGAAGAACACTTGCAGTTTGAA
GGACAGACCAAGGATAAACTAGGAAGCCCCCTAGCTCGCCCAGTTGTGGATGGAATAGTG
GCTGATAAGTTGACCTTTTTCCTTATGGAAAATGGGGAATTAGCTTCTAACCTCATCCGC
AAGGCTATCAAGGCCCGTGATGCTCGTGAAGCAGCACGTAAGGCGCGTGATGAGAGCCGA
AATGGGAAGAAAAACAAGAAAGATAAGGGCTTGTTGTCTGGGAAATTGACCCCAGCCCAA
TCTAAGAATCCTGCTAAGAATGAACTCTATCTAGTTGAGGGGGACTCTGCCGGTGGTTCT
GCCAAACAAGGTCGTGACCGCAAGTTCCAGGCTATTCTACCTCTTCGTGGTAAGGTTATC
AATACAGCCAAGGCCAAGATGGCGGATATCCTCAAAAATGAAGAGATCAATACCATGATT
TATACCATTGGTGCGGGTGTTGGAGCAGACTTCTCTATTGAAGATGCCAACTATGATAAG
ATCATTATCATGACCGATGCGGATACCGACGGTGCCCATATCCAGACCTTGCTCTTGACA
TTTTTCTACCGTTACATGCGTCCGCTAGTCGAGGCAGGTCATGTCTATATTGCCCTCCCA
CCTCTTTACAAGATGTCCAAAGGTAAAGGAAAGAAAGAAGAAGTGGCCTACGCTTGGACG
GACGGAGAACTAGAAGAACTCCGTAAACAGTTCGGTAAAGGCGCTACCCTCCAACGATAC
AAAGGACTTGGTGAGATGAATGCGGACCAGCTCTGGGAAACAACCATGAACCCAGAAACA
CGTACCCTCATCCGTGTCACAATTGAAGATTTAGCGCGCGCCGAACGCCGCGTCAATGTT
CTCATGGGAGATAAGGTAGAACCACGCCGTAAATGGATTGAAGATAATGTCAAGTTTACG
CTAGAAGAAGCGACAGTGTTTTAA

# Drug_Target_3_General_Function:
Replication, recombination and repair

# Drug_Target_3_General_References:
11463916	Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, Peterson S, Heidelberg J, DeBoy RT, Haft DH, Dodson RJ, Durkin AS, Gwinn M, Kolonay JF, Nelson WC, Peterson JD, Umayam LA, White O, Salzberg SL, Lewis MR, Radune D, Holtzapple E, Khouri H, Wolf AM, Utterback TR, Hansen CL, McDonald LA, Feldblyum TV, Angiuoli S, Dickinson T, Hickey EK, Holt IE, Loftus BJ, Yang F, Smith HO, Venter JC, Dougherty BA, Morrison DA, Hollingshead SK, Fraser CM: Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science. 2001 Jul 20;293(5529):498-506.
8763932	Pan XS, Fisher LM: Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J Bacteriol. 1996 Jul;178(14):4060-9.
8891124	Munoz R, De La Campa AG: ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob Agents Chemother. 1996 Oct;40(10):2252-7.
8913454	Tankovic J, Perichon B, Duval J, Courvalin P: Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob Agents Chemother. 1996 Nov;40(11):2505-10.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
6226

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
93132.2

# Drug_Target_3_Name:
DNA topoisomerase 4 subunit A

# Drug_Target_3_Number_of_Residues:
823

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00521	DNA_topoisoIV
PF03989	DNA_gyraseA_C

# Drug_Target_3_Protein_Sequence:
>DNA topoisomerase 4 subunit A
MSNIQNMSLEDIMGERFGRYSKYIIQDRALPDIRDGLKPVQRRILYSMNKDSNTFDKSYR
KSAKSVGNIMGNFHPHGDSSIYDAMVRMSQNWKNREILVEMHGNNGSMDGDPPAAMRYTE
ARLSEIAGYLLQDIEKKTVPFAWNFDDTEKEPTVLPAAFPNLLVNGSTGISAGYATDIPP
HNLAEVIDAAVYMIDHPTAKIDKLMEFLPGPDFPTGAIIQGRDEIKKAYETGKGRVVVRS
KTEIEKLKGGKEQIVIIEIPYEINKANLVKKIDDVRVNNKVAGIAEVRDESDRDGLRIAI
ELKKDANTELVLNYLFKYTDLQINYNFNMVAIDNFTPRQVGIVPILSSYIAHRREVILAR
SRFDKEKAEKRLHIVEGLIRVISILDEVIALIRASENKADAKENLKVSYDFTEEQAEAIV
TLQLYRLTNTDVVVLQEEEAELREKIAMLAAIIGDERTMYNLMKKELREVKKKFATPRLS
SLEDTAKAIEIDTASLIAEEDTYVSVTKAGYIKRTSPRSFAASTLEEIGKRDDDRLIFVQ
SAKTTQHLLMFTSLGNVIYRPIHELADIRWKDIGEHLSQTITNFETNEEILYVEVLDQFD
DATTYFAVTRLGQIKRVERKEFTPWRTYRSKSVKYAKLKDDTDQIVAVAPIKLDDVVLVS
QNGYALRFNIEEVPVVGAKAAGVKAMNLKEDDVLQSGFICNTSSFYLLTQRGSLKRVSIE
EILATSRAKRGLQVLRELKNKPHRVFLAGAVAEQGFVGDFFSTEVDVNDQTLLVQSNKGT
IYESRLQDLNLSERTSNGSFISDTISDEEVFDAYLQEVVTEDK

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Topoisomerase IV is essential for chromosome segregation. It has relaxation of supercoiled DNA activity. Performs the decatenation events required during the replication of a circular DNA molecule (By similarity)

# Drug_Target_3_SwissProt_ID:
P72525

# Drug_Target_3_SwissProt_Name:
PARC_STRPN

# Drug_Target_3_Synonyms:
Topoisomerase IV subunit A

# Drug_Target_3_Theoretical_pI:
5.35

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Cytoplasmic

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
11131958	Harding I, Simpson I: Fluoroquinolones: is there a different mechanism of action and resistance against Streptococcus pneumoniae? J Chemother. 2000 Oct;12 Suppl 4:7-15.
12835539	Hosaka M: [Antibacterial property and clinical effect of gatifloxacin, a novel quinolone antibacterial agent] Nippon Yakurigaku Zasshi. 2003 Jun;121(6):447-56.
15673722	Rafii F, Park M, Novak JS: Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones. Antimicrob Agents Chemother. 2005 Feb;49(2):488-92.
17253913	Kays MB, Zhanel GG, Reimann MA, Jacobi J, Denys GA, Smith DW, Wack MF: Selection of a gyrA mutation and treatment failure with gatifloxacin in a patient with Streptococcus pneumoniae with a preexisting parC mutation. Pharmacotherapy. 2007 Feb;27(2):221-6.
17970226	Mdluli K, Ma Z: Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect Disord Drug Targets. 2007 Jun;7(2):159-68.

# Drug_Target_4_Essentiality:
Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
Z67739

# Drug_Target_4_GenBank_ID_Protein:
1490399

# Drug_Target_4_GeneCard_ID:
parE

# Drug_Target_4_Gene_Name:
parE

# Drug_Target_4_Gene_Sequence:
>1944 bp
GTGTCAAAAAAGGAAATCAATATTAACAATTATAATGATGATGCTATTCAGGTGCTAGAA
GGGTTGGATGCGGTCCGAAAACGTCCGGGGATGTATATTGGATCGACCGATGGCGCTGGT
CTTCATCACCTAGTTTGGGAAATCGTTGATAATGCAGTCGATGAAGCCTTGTCTGGGTTT
GGTGATCGTATTGATGTAACTATCAATAAAGACGGTAGTCTAACGGTTCAAGACCATGGA
CGTGGGATGCCGACAGGTATGCACGCTATGGGAATTCCAACTGTTGAGGTTATCTTTACC
ATTCTTCATGCCGGAGGGAAATTCGGTCAAGGTGGCTATAAGACATCAGGTGGACTTCAC
GGAGTGGGTTCTTCCGTTGTTAACGCCCTTTCTAGCTGGTTAGAAGTTGAAATTACCCGT
GATGGCGCAGTTTACAAGCAACGTTTCGAAAATGGTGGAAAACCTGTCACGACTTTGAAG
AAAATCGGTACAGCACCCAAGTCTAAAACAGGCACCAAAGTTACTTTTATGCCTGACGCG
ACTATATTTTCTACGACAGATTTCAAGTACAATACCATTTCAGAGCGCCTTAATGAATCA
GCCTTTCTCTTGAAAAATGTGACCTTGTCTTTAACGGACAAGCGAACAGATGAAGCGATT
GAGTTCCACTATGAGAATGGAGTACAAGATTTTGTTTCTTATCTCAACGAAGATAAGGAA
ATCTTGACGCCAGTTCTTTACTTTGAAGGGGAAGACAATGGTTTTCAAGTGGAAGTAGCC
CTCCAGTACAATGACGGATTCTCAGATAACATTCTATCCTTTGTCAATAACGTTCGCACC
AAGGACGGTGGAACGCACGAGACAGGACTCAAGTCTGCCATTACCAAGGTCATGAATGAC
TATGCACGTAAAACAGGTCTTCTCAAGGAAAAAGATAAAAACCTTGAAGGTTCAGACTAT
CGTGAGGGACTAGCGGCCGTTCTTTCTATCTTAGTTCCTGAAGAACACTTGCAGTTTGAA
GGACAGACCAAGGATAAACTAGGAAGCCCCCTAGCTCGCCCAGTTGTGGATGGAATAGTG
GCTGATAAGTTGACCTTTTTCCTTATGGAAAATGGGGAATTAGCTTCTAACCTCATCCGC
AAGGCTATCAAGGCCCGTGATGCTCGTGAAGCAGCACGTAAGGCGCGTGATGAGAGCCGA
AATGGGAAGAAAAACAAGAAAGATAAGGGCTTGTTGTCTGGGAAATTGACCCCAGCCCAA
TCTAAGAATCCTGCTAAGAATGAACTCTATCTAGTTGAGGGGGACTCTGCCGGTGGTTCT
GCCAAACAAGGTCGTGACCGCAAGTTCCAGGCTATTCTACCTCTTCGTGGTAAGGTTATC
AATACAGCCAAGGCCAAGATGGCGGATATCCTCAAAAATGAAGAGATCAATACCATGATT
TATACCATTGGTGCGGGTGTTGGAGCAGACTTCTCTATTGAAGATGCCAACTATGATAAG
ATCATTATCATGACCGATGCGGATACCGACGGTGCCCATATCCAGACCTTGCTCTTGACA
TTTTTCTACCGTTACATGCGTCCGCTAGTCGAGGCAGGTCATGTCTATATTGCCCTCCCA
CCTCTTTACAAGATGTCCAAAGGTAAAGGAAAGAAAGAAGAAGTGGCCTACGCTTGGACG
GACGGAGAACTAGAAGAACTCCGTAAACAGTTCGGTAAAGGCGCTACCCTCCAACGATAC
AAAGGACTTGGTGAGATGAATGCGGACCAGCTCTGGGAAACAACCATGAACCCAGAAACA
CGTACCCTCATCCGTGTCACAATTGAAGATTTAGCGCGCGCCGAACGCCGCGTCAATGTT
CTCATGGGAGATAAGGTAGAACCACGCCGTAAATGGATTGAAGATAATGTCAAGTTTACG
CTAGAAGAAGCGACAGTGTTTTAA

# Drug_Target_4_General_Function:
Replication, recombination and repair

# Drug_Target_4_General_References:
11463916	Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, Peterson S, Heidelberg J, DeBoy RT, Haft DH, Dodson RJ, Durkin AS, Gwinn M, Kolonay JF, Nelson WC, Peterson JD, Umayam LA, White O, Salzberg SL, Lewis MR, Radune D, Holtzapple E, Khouri H, Wolf AM, Utterback TR, Hansen CL, McDonald LA, Feldblyum TV, Angiuoli S, Dickinson T, Hickey EK, Holt IE, Loftus BJ, Yang F, Smith HO, Venter JC, Dougherty BA, Morrison DA, Hollingshead SK, Fraser CM: Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science. 2001 Jul 20;293(5529):498-506.
8763932	Pan XS, Fisher LM: Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J Bacteriol. 1996 Jul;178(14):4060-9.
8891124	Munoz R, De La Campa AG: ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob Agents Chemother. 1996 Oct;40(10):2252-7.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
6227

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
71663.9

# Drug_Target_4_Name:
DNA topoisomerase 4 subunit B

# Drug_Target_4_Number_of_Residues:
647

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00204	DNA_gyraseB
PF00986	DNA_gyraseB_C
PF01751	Toprim
PF02518	HATPase_c

# Drug_Target_4_Protein_Sequence:
>DNA topoisomerase 4 subunit B
MSKKEININNYNDDAIQVLEGLDAVRKRPGMYIGSTDGAGLHHLVWEIVDNAVDEALSGF
GDRIDVTINKDGSLTVQDHGRGMPTGMHAMGIPTVEVIFTILHAGGKFGQGGYKTSGGLH
GVGSSVVNALSSWLEVEITRDGAVYKQRFENGGKPVTTLKKIGTAPKSKTGTKVTFMPDA
TIFSTTDFKYNTISERLNESAFLLKNVTLSLTDKRTNEAIEFHYENGVQDFVSYLNEDKE
ILTPVLYFEGEDNGFQVEVALQYNDGFSDNILSFVNNVRTKDGGTHETGLKSAITKVMND
YARKTGLLKEKDKNLEGSDYREGLAAVLSILVPEEHLQFEGQTKDKLGSPLARPVVDGIV
ADKLTFFLMENGELASNLIRKAIKARDAREAARKARDESRNGKKNKKDKGLLSGKLTPAQ
SKNPAKNELYLVEGDSAGGSAKQGRDRKFQAILPLRGKVVNTAKAKMADILKNEEINTMI
YTIGAGVGADFSIEDANYDKIIIMTDADTDGAHIQTLLLTFFYRYMRPLVEAGHVYIALP
PLYKMSKGKGKKEEVAYAWTDGELEELRKQFGKGATLQRYKGLGEMNADQLWETTMNPET
RTLIRVTIEDLARAERRVNVLMGDKVEPRRKWIEDNVKFTLEETTVF

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Topoisomerase IV is essential for chromosome segregation. It has relaxation of supercoiled DNA activity. Performs the decatenation events required during the replication of a circular DNA molecule (By similarity)

# Drug_Target_4_SwissProt_ID:
Q59961

# Drug_Target_4_SwissProt_Name:
PARE_STRPN

# Drug_Target_4_Synonyms:
Topoisomerase IV subunit B

# Drug_Target_4_Theoretical_pI:
6.77

# Drug_Target_4_Transmembrane_Regions:
None

#END_DRUGCARD DB01044
